Featured Articles
2026 Nasal & Inhalation Drug Development & Delivery eBook: Drug Repurposing Creates New Market Opportunities
In this exclusive seventh annual nasal and inhalation eBook, Drug Development & Delivery highlights how these routes of administration are bringing new life to orphaned drugs and open new opportunities for treatment beyond pulmonary and respiratory diseases. We also explore the challenges of nose-to-brain delivery, next-generation propellants, overcoming the limitations of dry powder inhalers, and successful formulation strategies.
SPECIAL FEATURE - Outsourcing Formulation Development & Manufacturing: Connecting Your Project to the Right Service Provider
Outsourcing formulation development and manufacturing can help drug developers address complex dosage forms, scale-up risks, regulatory demands, and accelerated timelines by connecting projects with CDMO partners that offer specialized expertise, integrated workflows, and scalable manufacturing support.
SPECIAL REPORT - Advancements in Respiratory Drug Delivery
Advances in inhaled drug delivery are improving how therapies reach the lungs, with innovations in formulations, devices, biologics, and digital tools helping expand treatment options for respiratory diseases.
EXECUTIVE INTERVIEW - Dr. Michalis Papadakis Founder & CEO Brainomix
Brainomix founder and CEO Dr. Michalis Papadakis discusses how AI-powered imaging is helping drug developers improve clinical trial design, identify meaningful treatment effects, and advance new therapies in stroke, pulmonary fibrosis, and other areas of unmet need.
CAR T CELL THERAPY - The Rise of Scalable Allogeneic CAR T: Shaping a New Era in Oncology
Allogeneic CAR T therapies are helping move oncology toward more scalable, off-the-shelf treatment models that could expand access, support earlier intervention, and bring advanced cell therapy closer to community cancer settings.
DRUG DELIVERY - Improved Prediction of Food Effect on Oral Absorption
Dissolution-permeation testing is helping drug developers better predict how food affects oral drug absorption by measuring both drug solubilization and membrane permeation, reducing the risk of misleading results from dissolution data alone.
DRUG-DEVICE COMBINATION PRODUCTS - Incorporating Self-Administered Drug-Device Combination Products Into Clinical Trials Can Bring Outsized Challenges & Outstanding Rewards
Self-administered drug-device combination products can bring major benefits to clinical trials, improving patient convenience, dosing consistency, compliance, and real-world insight, but they require careful early planning around usability, safety, regulatory requirements, compatibility, manufacturing, and scale-up.
DRUG DEVELOPMENT - Drug Combination Screening in Oncology: Advancing Predictive Strategies for Precision Drug Development
Drug combination screening is helping oncology developers identify synergistic drug pairs, connect response patterns to tumor biology, and support more predictive, biomarker-guided strategies for precision cancer treatment.
SINGLE B CELL ANTIBODY DISCOVERY - Improving Therapeutic Candidate Selection in Drug Development
Single B cell antibody discovery is helping improve therapeutic candidate selection by preserving native heavy- and light-chain pairing, accelerating sequence-defined screening, and enabling earlier identification of candidates with stronger specificity, function, and developability.
CHEMOENZYMATIC LIGATION - Enabling Scalable, Sustainable Oligonucleotide Manufacturing
Chemoenzymatic ligation offers a scalable, more sustainable path for oligonucleotide manufacturing by combining SPOS fragment production with enzymatic assembly to improve purity, reduce impurities, and support growing demand for nucleic acid therapeutics.
CONTROLLED RELEASE - Precision in Every Dose: Advancing Controlled Release for Small Molecule Therapeutics
Controlled release technologies are helping small molecule therapeutics deliver more consistent drug exposure, improve patient adherence, reduce dosing frequency, and support more precise treatment through advanced formulation and delivery strategies.
BIOCATALYSIS - Biocatalysis Without Barriers for Efficient Small Molecule Process Development
Masha Kononov and Reuben Carr examine both the promise and the practical constraints of biocatalysis in modern drug substance development, as well as the role of contract research, development and manufacturing organizations (CRD-MOs) in meeting the evolving demands of modern small molecule synthesis.
SPECIAL FEATURE - PFS & Parenteral Manufacturing: Rapid Growth of Injectables Places Unprecedented Demands on Parenteral Manufacturing
Contributor Cindy H. Dubin highlights many of these CDMOs as well as innovations in the PFS sector.
FORMULATION FORUM - Supercritical Carbon Dioxide (scCO2) for Improving Solubility & Oral Bioavailability of Drugs
Shaukat Ali, PhD, and Jim Huang, PhD, discuss as more new chemical entities coming out of discovery are poorly soluble (BCS Class II and IV), the scCO2 is taking an aim to find the desired solutions to help improve the bottleneck in the industry.
TKIS - Next-Generation BCR-ABL TKIs for CML: The Allosteric Era
Emil Kuriakose, MD, explores the current CML treatment landscape, ongoing clinical challenges, and the potential of next-generation TKIs currently in development, offering hope for the growing CML community.
SELF ADMINISTRATION - Smarter, Kinder, Simpler: EcoSafe Sets a New Standard for Sustainable Self-Administration
Mark Glass takes a novel approach to serve a patient group, with the ambitious aims of increasing the inclusivity of its existing 1mL safety syringe, simplifying procurement, reducing cost, and reducing carbon footprint.
EXCIPIENTS - Strategic Excipient Sourcing: Navigating Supply Chain Resilience, Quality & Sustainability by Design
Nick DiFranco, MEM, explores the critical considerations drug developers must evaluate when selecting an excipient partner today.
EXECUTIVE INTERVIEW - Resilience: From Complexity to Clarity - Sharpening Focus for Long-Term Performance in a More Demanding CDMO Era
Catherine Hanley, VP, Head of Marketing and Corporate Communications, explains how the company has rebalanced its network and aligned around its core strengths in biologics and sterile fill/finish manufacturing.
IPSC-NK THERAPIES - Advancing Allogeneic Platforms: The Future of Scalable iPSC-NK Therapies
Stefan Braam, PhD, explores how developers across the industry are tackling these challenges through process optimization, automation, and gene editing innovations. These efforts aim to deliver robust, cost-effective allogeneic platforms that meet the demands of modern healthcare.
EXECUTIVE INTERVIEW - Vetter Pharma: Why Fill-Finish Matters More Than Ever – & the Trends Behind It
Carsten Press, one of Vetter’s Managing Directors, discusses the key trends shaping CDMO innovation in today’s dynamic market – and how the family-owned company is integrating these trends into its forward-looking strategy to support consistent quality and seamless drug delivery.
